The management of antiphospholipid syndrome is hindered by heterogeneous clinical presentations. Whole-blood transcriptomics have the potential to identify previously unknown disease endotypes, which could inform new treatment strategies. However, such hypothesis-generating data must still account for the results of randomized clinical trials, such as those focused on direct oral anticoagulants in APS.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Nikolopoulos, D. et al. Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events. Ann. Rheum. Dis. https://doi.org/10.1136/ard-2024-225664 (2024).
Xourgia, E. & Tektonidou, M. G. Type I interferon gene expression in antiphospholipid syndrome: Pathogenetic, clinical and therapeutic implications. J. Autoimmun. 104, 102311 (2019).
Verrou, K. M., Sfikakis, P. P. & Tektonidou, M. G. Whole blood transcriptome identifies interferon-regulated genes as key drivers in thrombotic primary antiphospholipid syndrome. J. Autoimmun. 134, 102978 (2023).
Tambralli, A., Gockman, K. & Knight, J. S. NETs in APS: current knowledge and future perspectives. Curr. Rheumatol. Rep. 22, 67 (2020).
Pappa, M. et al. Augmented oxidative stress, accumulation of DNA damage and impaired DNA repair mechanisms in thrombotic primary antiphospholipid syndrome. Clin. Immunol. 254, 109693 (2023).
Wozniak, E., Broncel, M., Bukowska, B. & Gorzelak-Pabis, P. The protective effect of dabigatran and rivaroxaban on DNA oxidative changes in a model of vascular endothelial damage with oxidized cholesterol. Int. J. Mol. Sci. 21, 1953 (2020).
Goldhaber, S. Z. et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: findings from RE-COVER(R), RE-COVER II, and RE-MEDY. Vasc. Med. 21, 506–514 (2016).
Tektonidou, M. G. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann. Rheum. Dis. 78, 1296–1304 (2019).
Zuily, S. et al. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J. Thromb. Haemost. 18, 2126–2137 (2020).
Khairani, C. D. et al. Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials. J. Am. Coll. Cardiol. 81, 16–30 (2023).
Acknowledgements
We thank M. Crowther, P. Meroni and V. Pengo for helpful conversations on this subject.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Knight, J.S., Tektonidou, M.G. Can transcriptomics guide the management of SLE-associated APS?. Nat Rev Rheumatol (2024). https://doi.org/10.1038/s41584-024-01123-7
Published:
DOI: https://doi.org/10.1038/s41584-024-01123-7